Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4224-4232

  Xie, Yunjie ^a   Gilbert, Jeff D ^a   Kim, Jae Ho ^a   Freytag, Svend O ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL CYCLE G2 PHASE; CELL KILLING; DRUG EFFICACY; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GANCICLOVIR; GENE THERAPY; GENES, P53; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NUCLEOSIDE DEAMINASES; OVARIAN NEOPLASMS; THYMIDINE KINASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033402277     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Devita, V. Principles of cancer management: chemotherapy. In: V. Devita, Hellman, and Rosenberg (eds.), Cancer: Principles & Practice of Oncology, pp. 333-347. Philadelphia: Lippincott, 1997.
2. Evan, G., and Littlewood, T. A matter of life and death. Science (Washington DC), 281: 1317-1322, 1998.
3. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53- dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
4. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
5. Davidoff, A. M., Herndon, J. E., Glover, N. S., Kerns, B. J., Pence, J. C., Iglehart, J. D., and Marks, J. R. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery, 110: 259-264, 1991.
6. Thorlacius, S., Borresen, A. L., and Eyfjord, J. E. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res., 53: 1637-1641, 1993.
7. Wattel, E., Preudhomme, C., and Hecquet, B. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84: 3148-3157, 1994.
8. Dohner, H., Fischer, K., and Benz, M. p53 gene deletion predicts poor survival and non-response to therapy with purine analogs in chronic B-cell leukemia. Blood, 85: 1580-1589, 1995.
9. Brachman, D., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
10. Volm, M., Efferth, T., and Mattern, J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung: clinical and biological considerations. Anticancer Res., 12: 11-20, 1992.
11. Gasparini, G., Weidner, N., and Maluta, S. Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cell carcinoma. Int. J. Cancer, 55: 739-744, 1993.
12. Van Der Zee, A., Hollema, H., and Suurmeijer, A. Value of P- glycoprotein, glutathione S-transferase, c-erbB2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol., 13: 70-78, 1995.
13. Blaese, R. M. Gene therapy for cancer. Sci. Am., 2766: 111-115, 1997.
14. Mullen, C., Kilstrup, M., and Blaese, R. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
15. Huber, B., Austin, E., Good, S., Knick, V., Tibbels, S., and Richards. C. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
16. Moolten, F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
17. Rogulski, K. R., Kim, J. H., Kim, S. H., and Freytag, S. O. Glioma cells transduced with an E. coli CD/HSV-1TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther., 8: 73-85, 1997.
18. Rogulski, K. R., Zhang, K., Kolozsvary, A., Kim, J. H., and Freytag, S. O. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin. Cancer Res., 3: 2081-2088, 1997.
19. Khil, M. S., Kim, J. H., Mullen, C. A., Lim, S. H., and Freytag, S. O. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin. Cancer Res., 2: 53-57, 1996.
20. Kim, J. H., Kim, S. H., Brown, S. L., and Freytag, S. O. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res., 54: 6053-6056, 1994.
21. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., and Kim, J. H. A novel three-pronged approach to selectively kill cancer cells: concomitant viral, double suicide gene and radiotherapy. Hum. Gene Ther., 9: 1323-1333, 1998.
22. Gable, M., Kim, J. H., Kolozsvary, A., Khil, M., and Freytag, S. O. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int. J. Radiat. Oncol., 41: 883-887, 1998.
23. Kim, J. H., Kolozsvary, A., Rogulski, K., Khil, M. S., Brown, S. L., and Freytag, S. O. Selective radiosensitization of 91 gliomas in the brain transduced with double suicide fusion gene. Cancer J. Sci. Am., 4: 2-7, 1998.
24. Bett, A., Haddara, W., Prevec, L., and Graham, F. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA, 91: 8802-8806, 1994.
25. Baker, S., Markowitz, S., Fearon, E., Willson, J., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
26. Adelmant, G., Gilbert, J., and Freytag, S. O. Human TLS-CHOP oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPβ function. J. Biol. Chem., 273: 15574-15581, 1998.
27. Miller, A. D., and Rosman, G. Improved retroviral vectors for gene transfer and expression. BioTechniques, 7: 980-990, 1989.
28. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., and Kinzler, K. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
29. Han, J., Sabbatini, P., Perez, D., Rao, L., Modha, D., and White, E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev., 10: 461-477, 1997.
30. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7: 546-554, 1993.